文献速递流行病学与生物统计临床试验与 GCP

哮喘与湿疹随机对照试验中补救用药处理不足:一项系统综述

Current approaches to handling rescue medication in asthma and eczema randomized controlled trials are inadequate: a systematic review.
PubMed 文献 · J Clin Epidemiol · 2020-06-03

该系统综述纳入60项评估单克隆抗体治疗慢性湿疹或哮喘的II/III期随机对照试验,检索EMBASE、MEDLINE和Cochrane对照试验中心注册库。全部试验允许使用补救用药,但仅47%报告使用情况,45%按组汇总且安慰剂组平均多使用25%(95%CI 17%-36%),仅15%进行分析校正且多数方法欠佳。

要点

  • 哮喘与湿疹单抗RCT普遍允许补救用药,但仅47%报告其使用情况。
  • 安慰剂组补救用药平均多25%(95%CI 17%-36%),提示组间不均衡。
  • 仅15%试验校正补救用药,且多数用单次填补等次优方法可能引入偏倚。

核心结论

  • 评估单克隆抗体的哮喘与湿疹RCT中补救用药常被允许但未常规报告,组间使用不均衡且少有研究估计校正后疗效。
  • 少数进行分析校正的试验方法欠佳,可能引入偏倚。

研究设计与样本

  • 系统综述,纳入评估单克隆抗体治疗慢性湿疹或哮喘的II/III期随机对照试验。
  • 检索EMBASE、MEDLINE和Cochrane对照试验中心注册库,共纳入60项已发表RCT。

主要发现

  • 60项试验(100%)允许使用补救用药,但仅28项(47%)报告其使用情况。
  • 9项试验(15%)进行了校正补救用药的疗效分析,其中8项使用单次填补等次优方法。
  • 上述8项中4项在将补救后数据设为缺失后采用末次观测结转(LOCF)。

临床怎么用

  • 解读哮喘与湿疹单抗RCT时应关注补救用药是否报告及组间是否均衡。
  • 对未校正补救用药的试验,疗效估计可能受组间补救用药差异影响。

局限性

  • 仅纳入评估单克隆抗体的II/III期RCT,未涵盖其他类型干预。
  • 仅检索EMBASE、MEDLINE和Cochrane对照试验中心注册库。
  • 未报告所纳入试验的样本量、P值及偏倚风险评估细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objective of this study was to examine how rescue medication is defined, reported, and accounted for in randomized controlled trials (RCTs) in eczema and asthma populations. STUDY DESIGN AND SETTING: This is a systematic review of phase II/III RCTs evaluating monoclonal antibodies for treating chronic eczema or asthma. A search of EMBASE, MEDLINE, and the Cochrane Central Register of Controlled Trials was conducted to identify eligible RCTs. RESULTS: Sixty published RCTs were identified, of which 60 (100%) allowed use of rescue medication but only 28 (47%) reported its use. Twenty-seven (45%) articles summarized rescue use by arm, with an average of 25% (95% CI (17%, 36%)) greater use in the placebo arm. Nine (15%) trials undertook an analysis that adjusted the primary treatment effect estimate for rescue medication use, but 8 of these used a suboptimal approach using single imputation, including 4 which used "last observation carried forward" after setting postrescue data to missing. CONCLUSION: Rescue medication use in eczema and asthma trials evaluating monoclonal antibodies is often permitted, but not routinely reported. There is evidence of imbalance in rescue use between arms, but few articles attempted to estimate a rescue-adjusted treatment effect. In trials that did, the methods used were suboptimal which could introduce bias.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Chis Ster AM, Cornelius V, Cro S, et al. Current approaches to handling rescue medication in asthma and eczema randomized controlled trials are inadequate: a systematic review. J Clin Epidemiol. 2020. PMID: 32504781. doi:10.1016/j.jclinepi.2020.05.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。